Abstract |
Neoplastic melanocytes may exhibit certain differentiation characteristics of other neural-crest derivatives. We aimed to study the expression of microtubule-associated protein 2 (MAP-2) in different types of melanocytic skin lesions. Paraffin-embedded sections of 42 benign nevi (BN), 22 dysplastic nevi (DN), 45 superficial spreading melanomas (SSMs), and 15 subcutaneous melanoma metastases were immunohistologically assessed using the monoclonal mouse MAP-2ab antibody (Zytomed, Berlin, Germany). The percentage MAP-2 expression of DN and SSMs was significantly increased compared with BN. Moreover, subcutaneous melanoma metastases showed significantly decreased MAP-2 expression compared with DN and SSMs. In SSMs, MAP-2 expression significantly correlated with the Breslow vertical tumor thickness, Clark level, and stage of disease. We observed that MAP-2 is differentially expressed during the development and progression of benign and malignant melanocytic skin lesions. In contrast with the findings of previous studies, our data indicate that MAP-2 is a moderately positive predictor of the progression of SSMs.
|
Authors | Thilo Gambichler, Sebastian Rotterdam, Katharina Radkowski, Peter Altmeyer, Alexander Kreuter |
Journal | American journal of clinical pathology
(Am J Clin Pathol)
Vol. 131
Issue 5
Pg. 710-4
(May 2009)
ISSN: 1943-7722 [Electronic] England |
PMID | 19369632
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- MAP2 protein, human
- Microtubule-Associated Proteins
|
Topics |
- Biomarkers, Tumor
(metabolism)
- Disease Progression
- Dysplastic Nevus Syndrome
(metabolism, pathology)
- Female
- Humans
- Immunohistochemistry
- Male
- Melanocytes
(metabolism, pathology)
- Melanoma
(metabolism, secondary)
- Microtubule-Associated Proteins
(metabolism)
- Middle Aged
- Neoplasm Staging
- Nevus, Pigmented
(metabolism, pathology)
- Skin Neoplasms
(metabolism, pathology)
|